Benjamin Linas

In response to the growing opioid epidemic in the United States, there is an increased focus on expanding evidence-based treatment using medications prescribed for substance use disorder, especially medications that can be prescribed in outpatient settings including buprenorphine and naltrexone. The Surgeon General’s report on facing addiction in America describes substance use disorders as chronic illnesses requiring […]

In the opening plenary panel of the CHERISH (Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV and HIV) conference on evidence-based policy and practice are (l to r) Daniel Polsky, PhD, moderator and Executive Director of the University of Pennsylvania’s Leonard Davis Institute of Health Economics (LDI); Tom McLellan, PhD, Chairman of the Board and […]

The Center for Health Economics of Treatment Interventions for Substance Use Disorders, HCV, and HIV (CHERISH) was profiled at the Liver Meeting® 2016 in Boston, MA. The Center’s mission is to develop and disseminate health economic research on healthcare utilization, health outcomes, and health-related behaviors that informs substance use disorder treatment policy and HCV and […]

Dr. Alysse Wurcel is an infectious disease specialist and faculty member at Tufts University School of Medicine with a focus in HIV and hepatitis C (HCV) infection whose research interests closely align with her clinical work. Dr. Wurcel’s research is focused on the treatment of HCV in people who inject drugs (PWID), people in the criminal […]

The high costs of treating the more than 7 million people with a substance use disorder may be daunting to public and private payers. The costs of not treating them may be even higher, especially if you consider the costs of failing to screen for and treat HIV and hepatitis C in this population. Sorting […]